Cornerstone Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.6M Sell
154,682
-2,775
-2% -$616K 3.36% 6
2025
Q4
$36M Sell
157,457
-949
-0.6% -$216K 3.55% 7
2025
Q3
$36.7M Buy
158,406
+782
+0.5% +$159K 3.59% 6
2025
Q2
$29.3M Sell
157,624
-7,156
-4% -$1.33M 3.06% 9
2025
Q1
$34.5M Sell
164,780
-2,306
-1% -$448K 3.72% 4
2024
Q4
$29.7M Sell
167,086
-15,741
-9% -$2.89M 3.13% 7
2024
Q3
$36.1M Buy
182,827
+1,638
+0.9% +$306K 3.37% 6
2024
Q2
$31.1M Sell
181,189
-4,787
-3% -$793K 3.13% 8
2024
Q1
$33.9M Sell
185,976
-10,915
-6% -$1.88M 3.47% 5
2023
Q4
$30.5M Sell
196,891
-1,134
-0.6% -$165K 3.34% 7
2023
Q3
$29.5M Sell
198,025
-3,711
-2% -$545K 3.56% 6
2023
Q2
$27.2M Buy
201,736
+594
+0.3% +$87.1K 3.14% 9
2023
Q1
$32.1M Sell
201,142
-680
-0.3% -$104K 3.87% 5
2022
Q4
$32.6M Sell
201,822
-1,575
-0.8% -$241K 4.18% 5
2022
Q3
$27.3M Buy
203,397
+1,187
+0.6% +$170K 3.84% 4
2022
Q2
$31M Sell
202,210
-4,938
-2% -$755K 3.97% 5
2022
Q1
$33.6M Sell
207,148
-20,319
-9% -$2.95M 3.77% 4
2021
Q4
$30.8M Buy
227,467
+2,080
+0.9% +$246K 3.28% 8
2021
Q3
$24.3M Buy
225,387
+3,255
+1% +$372K 2.8% 12
2021
Q2
$25M Buy
222,132
+3,188
+1% +$359K 2.84% 12
2021
Q1
$23.7M Buy
218,944
+4,693
+2% +$502K 2.87% 12
2020
Q4
$23M Sell
214,251
-1,079
-0.5% -$104K 2.95% 14
2020
Q3
$18.9M Buy
215,330
+6,498
+3% +$612K 2.72% 17
2020
Q2
$20.5M Buy
208,832
+3,405
+2% +$300K 3.49% 10
2020
Q1
$15.7M Buy
205,427
+10,477
+5% +$892K 3.25% 13
2019
Q4
$17.3M Buy
194,950
+22,637
+13% +$1.88M 2.43% 19
2019
Q3
$13M Sell
172,313
-2,210
-1% -$152K 2.03% 25
2019
Q2
$12.7M Sell
174,523
-6,125
-3% -$481K 1.99% 22
2019
Q1
$14.6M Sell
180,648
-2,770
-2% -$227K 2.41% 21
2018
Q4
$16.9M Sell
183,418
-2,395
-1% -$211K 3.01% 16
2018
Q3
$17.6M Sell
185,813
-930
-0.5% -$88.2K 2.67% 20
2018
Q2
$17.3M Sell
186,743
-7,839
-4% -$766K 2.94% 17
2018
Q1
$18.4M Sell
194,582
-1,486
-0.8% -$163K 3.03% 16
2017
Q4
$19M Sell
196,068
-17,905
-8% -$1.69M 3.22% 10
2017
Q3
$19M Sell
213,973
-9,691
-4% -$738K 3.33% 7
2017
Q2
$16.2M Buy
223,664
+1,003
+0.5% +$67.4K 3.09% 13
2017
Q1
$14.5M Buy
222,661
+971
+0.4% +$61K 2.84% 16
2016
Q4
$13.9M Sell
221,690
-14,289
-6% -$872K 2.97% 14
2016
Q3
$14.9M Buy
235,979
+3,355
+1% +$217K 3.21% 14
2016
Q2
$14.4M Sell
232,624
-3,490
-1% -$213K 3.14% 16
2016
Q1
$13.5M Buy
236,114
+5,490
+2% +$306K 2.97% 18
2015
Q4
$13.7M Buy
230,624
+3,603
+2% +$208K 3.09% 17
2015
Q3
$12.4M Buy
227,021
+7,652
+3% +$498K 3.08% 17
2015
Q2
$14.7M Sell
219,369
-1,710
-0.8% -$112K 3.4% 7
2015
Q1
$12.9M Buy
221,079
+3,235
+1% +$195K 3.37% 13
2014
Q4
$14.3M Sell
217,844
-6,756
-3% -$426K 3.77% 8
2014
Q3
$13M Sell
224,600
-5,545
-2% -$308K 3.6% 11
2014
Q2
$13M Buy
230,145
+5,903
+3% +$310K 3.5% 13
2014
Q1
$11.5M Buy
224,242
+9,199
+4% +$465K 3.3% 16
2013
Q4
$11.4M Buy
215,043
+4,115
+2% +$202K 3.33% 17
2013
Q3
$9.44M Buy
210,928
+1,530
+0.7% +$67.8K 2.88% 18
2013
Q2
$8.66M Buy
+209,398
New +$9.16M 2.84% 18

Other funds holding ABBV

Cornerstone Capital's ABBV Position: Q1 2026 in Review

Cornerstone Capital reduced its AbbVie (ABBV) stake by 1.8% in Q1 2026, selling an estimated $616K and leaving 154,682 shares worth $33.6M. The position accounts for 3.36% of the portfolio, ranked #6.

Cornerstone Capital first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $36.7M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cornerstone Capital held 154,682 shares of AbbVie worth $33.6M as of Q1 2026.
  • Cornerstone Capital sold 2,775 AbbVie shares in Q1 2026, an estimated $616K.
  • AbbVie made up 3.36% of Cornerstone Capital's portfolio in Q1 2026, its #6 holding.
  • Cornerstone Capital first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Cornerstone Capital's AbbVie position peaked at $36.7M in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cornerstone Capital's 13F filing for Q1 2026, filed 12 May 2026.